ZyVersa Therapeutics (ZVSA) Stock Price, Quote, News & History

Comments

ZyVersa Therapeutics Inc (ZVSA) Stock Price, Quote, News & History

ZVSAOTCQB

Trade with Public

$0.3113

At close: Jul 25, 5:00 PM EST

OverviewNews Earnings Analyst Ratings Short Interest

Key Statistics

Open

Volume / Avg.

29.65K / 60.24K

Day Range

- - -

52 Wk Range

0.11 - 1.67

Market Cap

$1.62M

P/E Ratio

Dividend Yield

Exchange

OTC

RSI

Short Interest

Days to Cover

5.75

Recent Zyversa Therapeutics Inc News

Why Did ZyVersa Therapeutics Stock Shoot Higher On Tuesday?

ZyVersa gains FDA approval for emergency use of VAR 200 in a rare kidney disease case; stock jumps on high trading volume and regulatory momentum.

Vandana Singh

Dow Jumps 400 Points; Yum! Brands Posts Downbeat Earnings

Avi Kapoor

S&P 500 Gains 1%; Vimeo Shares Spike Higher

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-5.11M

Investing Cash Flow (TTM)

Financing Cash Flow (TTM)

3.69M

Free Cash Flow (TTM)

-5.11M

Capital Expenditure (TTM)

Net Change in Cash (TTM)

-1.43M

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$1.52M

PE Ratio (TTM)

PE Ratio (FWD)

PEG Ratio (TTM)

PS Ratio (TTM)

PB Ratio (TTM)

Earnings Yield % (TTM)

-2200.00%

Earnings Yield % (FWD)

EV / EBITDA (TTM)

Price / EBITDA (TTM)

Price / Free Cash Flow (TTM)

Book Value / Share

-$1.53

Company Debt

Total Debt

LT Debt

LT Debt Issuance (TTM)

LT Debt Repayment (TTM)

Total Cash

$101.78K

Debt to Equity

Issuance of Debt (TTM)

Repayment of Debt (TTM)

Key Statistics

Open

Volume / Avg.

29.65K / 60.24K

Day Range

- - -

52 Wk Range

0.11 - 1.67

Market Cap

$1.62M

P/E Ratio

Dividend Yield

Exchange

OTC

RSI

Short Interest

Days to Cover

5.75

About

Sector

Health Care

Industry

Biotechnology

ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary global...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy ZyVersa Therapeutics (ZVSA) stock?

You can purchase shares of ZyVersa Therapeutics (OTCQB:ZVSA) through any online brokerage.

View our list of the best stock brokerages

Who are ZyVersa Therapeutics (ZVSA) competitors?

There are no as such competitors for ZyVersa Therapeutics.

What is the forecast, or price target, for ZyVersa Therapeutics (ZVSA) stock?

ZyVersa Therapeutics has a consensus price target of $12.00.

What is the current price for ZyVersa Therapeutics (ZVSA)?

The stock price for ZyVersa Therapeutics (OTCQB: ZVSA) is $0.200503 last updated April 10, 2026 at 3:32 PM EDT.

Does ZyVersa Therapeutics (ZVSA) pay a dividend?

There are no upcoming dividends for ZyVersa Therapeutics.

When is ZyVersa Therapeutics (OTCQB:ZVSA) reporting earnings?

ZyVersa Therapeutics does not have any upcoming earnings scheduled.

Is ZyVersa Therapeutics (ZVSA) going to split?

There is no upcoming split for ZyVersa Therapeutics.

What sector and industry does ZyVersa Therapeutics (ZVSA) operate in?

ZyVersa Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the OTCQB.

Key Statistics

Open

Volume / Avg.

29.65K / 60.24K

Day Range

- - -

52 Wk Range

0.11 - 1.67

Market Cap

$1.62M

P/E Ratio

Dividend Yield

Exchange

OTC

RSI

Short Interest

Days to Cover

5.75

Recent Zyversa Therapeutics Inc News

Why Did ZyVersa Therapeutics Stock Shoot Higher On Tuesday?

ZyVersa gains FDA approval for emergency use of VAR 200 in a rare kidney disease case; stock jumps on high trading volume and regulatory momentum.

Vandana Singh

Dow Jumps 400 Points; Yum! Brands Posts Downbeat Earnings

Avi Kapoor

S&P 500 Gains 1%; Vimeo Shares Spike Higher

Avi Kapoor